Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry

Background: Large cohort studies of patients with COVID-19 treated with remdesivir have reported improved clinical outcomes, but data on older patients are scarce. Objective: This work aims to assess the potential benefit of remdesivir in unvaccinated very old patients hospitalized with COVID-19; (2...

ver descrição completa

Detalhes bibliográficos
Autores: Ramos-Rincón, José Manuel, López Carmona, María Dolores, Cobos Palacios, Lidia, López Sampalo, Almudena, Rubio Rivas, Manuel, Martín Escalante, María Dolores, Cossio Tejido, Santiago de, Taboada-Martínez, María Luisa, Muiño Miguez, Antonio, Areses Manrique, Maria, Martínez Cilleros, Carmen, Tuñón de Almeida, Carlota, Abella Vázquez, Lucy, Martínez Gonzalez, Angel Luís, Díez García, Luis Felipe, Ripper, Carlos Jorge, Asensi, Victor, Martinez Pascual, Angeles, Guisado Vasco, Pablo, Lumbreras Bermejo, Carlos, Gómez Huelgas, Ricardo, The Semi-covid-19 Network
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2022
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositório:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/187949
Acesso em linha:https://hdl.handle.net/2445/187949
Access Level:Acceso aberto
Palavra-chave:COVID-19
SARS-CoV-2
Persones grans
Malalts hospitalitzats
Older people
Hospital patients
Descrição
Resumo:Background: Large cohort studies of patients with COVID-19 treated with remdesivir have reported improved clinical outcomes, but data on older patients are scarce. Objective: This work aims to assess the potential benefit of remdesivir in unvaccinated very old patients hospitalized with COVID-19; (2) Methods: This is a retrospective analysis of patients >= 80 years hospitalized in Spain between 15 July and 31 December 2020 (SEMI-COVID-19 Registry). Differences in 30-day all-cause mortality were adjusted using a multivariable regression analysis. (3) Results: Of the 4331 patients admitted, 1312 (30.3%) were >= 80 years. Very old patients treated with remdesivir (n: 140, 10.7%) had a lower mortality rate than those not treated with remdesivir (OR (95% CI): 0.45 (0.29-0.69)). After multivariable adjustment by age, sex, and variables associated with lower mortality (place of COVID-19 acquisition; degree of dependence; comorbidities; dementia; duration of symptoms; admission qSOFA; chest X-ray; D-dimer; and treatment with corticosteroids, tocilizumab, beta-lactams, macrolides, and high-flow nasal canula oxygen), the use of remdesivir remained associated with a lower 30-day all-cause mortality rate (adjusted OR (95% CI): 0.40 (0.22-0.61) (p < 0.001)). (4) Conclusions: Remdesivir may reduce mortality in very old patients hospitalized with COVID-19.

Registros relacionados